MabVax Therapeutics (MBVXQ) Stock Price, News & Analysis

Company Overview

MabVax Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based therapies for the treatment and diagnosis of solid tumors. The company’s lead programs target carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), an antigen overexpressed in a variety of epithelial cancers. By leveraging monoclonal and radiolabeled antibody platforms, MabVax aims to deliver both therapeutic and imaging agents to improve detection and treatment of CEACAM5-expressing tumors.

The company’s pipeline includes MVT-5873, a fully human monoclonal antibody directed against CEACAM5, currently evaluated in early-stage clinical trials for safety, pharmacokinetics and preliminary anti-tumor activity. In parallel, MabVax is advancing MVT-1075, a radiolabeled imaging agent designed to detect CEACAM5-positive malignancies via positron emission tomography (PET). Both programs reflect the company’s integrated approach to companion diagnostics and targeted therapy, potentially enabling patient selection and treatment monitoring in real time.

Headquartered in San Diego, California, MabVax conducts its research and development activities in the United States while seeking collaborations to support global clinical studies. The company was founded on a platform of translational oncology research, with its technology originating from academic partnerships. Governance and oversight are provided by an experienced management team and board of directors with backgrounds in oncology drug development, immunology and clinical research.

As a clinical-stage enterprise, MabVax continues to explore additional product candidates that leverage its proprietary antibody engineering capabilities. Beyond CEACAM5, the company is investigating other tumor-associated antigens to broaden its pipeline and address unmet needs in oncology. Through its focused R&D strategy, MabVax aims to advance precision medicine solutions for patients with hard-to-treat cancers.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.02
• 52-Week Range: $0.00 to $0.30
• Volume: 1,333 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MBVXQ Stock Analysis - Frequently Asked Questions

How have MBVXQ shares performed this year?

MabVax Therapeutics' stock was trading at $0.0230 at the start of the year. Since then, MBVXQ shares have increased by 0.0% and is now trading at $0.0230.

How do I buy shares of MabVax Therapeutics?

Shares of MBVXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MBVXQ
• CIK: N/A
• Web: www.mabvax.com
• Phone: 858-259-9405
• Fax: 650-845-7800
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A